ArticleCureus2026
Microcystic Adnexal Carcinoma: A Rare and Locally Aggressive Adnexal Neoplasm.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microcystic adnexal carcinoma (MAC) is a rare, locally aggressive cutaneous neoplasm with a high potential for local recurrence. It primarily affects the head and neck region and is thought to arise from pluripotent adnexal keratinocytes. The tumor is characterized by slow, progressive growth. A 70-year-old man presented with a lesion in the right supraorbital region, consisting of an irregular, yellowish, firm, and poorly defined plaque. A punch biopsy revealed an infiltrative neoplasm composed of nests and cords of atypical basaloid cells. The patient underwent Mohs micrographic surgery followed by reconstruction using an advancement flap incorporating superior and inferior Burow's triangles. The postoperative course was uneventful, with no evidence of recurrence after six months of follow-up. MAC is a rare cutaneous neoplasm that is frequently underdiagnosed and has a high risk of local recurrence if not completely excised. Mohs micrographic surgery is the treatment of choice because it allows complete margin assessment while maximizing tissue preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.